GLP-1 Medicines Promote Weight Loss While Preserving Muscle Mass and Function

Obesity is a global health crisis, and GLP-1 receptor agonists have emerged as highly effective treatments for significant weight reduction. However, a common concern with rapid weight loss, regardless of method, is the potential for sarcopenia (age-related muscle loss) or a disproportionate loss of lean muscle mass alongside fat mass, which can negatively impact metabolic health and physical function. This study specifically addresses whether weight loss induced by GLP-1 medicines leads to a disproportionate loss of muscle mass or function in both preclinical and clinical settings.

The study revealed that GLP-1-induced weight loss preferentially targeted fat mass while largely preserving muscle. In obese mice, semaglutide treatment resulted in a 22% reduction in body weight, with only 2.5% attributed to lean mass loss, compared to 15% lean mass loss in diet-restricted controls achieving similar total weight loss. Human participants on tirzepatide experienced an average body weight reduction of 18.5%, of which only 3.1% was lean muscle mass, significantly lower than the 9.8% lean mass loss observed in a matched diet-only control group. Muscle function, as measured by grip strength and functional tests, showed no significant decline in either GLP-1 treated group (p>0.05).